Skip to main content

Security report for pallapharma.com

Palla Pharma Norway · Healthcare · Norway

Medium risk. 6 critical or high findings in Security headers, SSL/TLS and 1 other check.

Security score

55/100

Risk levelMedium

0–100, higher is better. How it is calculated

Palla Pharma Norway is a pharmaceutical company specializing in the production of active pharmaceutical ingredients (API) and finished dose formulations (FDF) for a global market. The company appears to be relatively new, founded in 2019, and targets pharmaceutical industry clients worldwide. The website is built on WordPress using the Divi theme, with multilingual support and GDPR cookie compliance mechanisms in place. The technical infrastructure includes modern web technologies and tracking tools such as Google Analytics and Google Tag Manager. Security posture is adequate with HTTPS enabled and good SSL configuration; however, the absence of security headers and explicit privacy policies indicates room for improvement. Contact information and security policies are not explicitly provided, which could affect user trust and compliance. Overall, the website presents a professional image with good content quality and technical implementation but would benefit from enhanced privacy and security disclosures.

Scanned

NIS2 and GDPR posture

GDPR outside view
95/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

6 findings rated critical or high. Fix these first.

  1. Security headers

    Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.

    • High

      Missing Strict-Transport-Security header

      Forces HTTPS connections

      What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"

      • CWE-319
      • OWASP A04:2025
      • ASVS V3.4.1
    • High

      Missing X-Frame-Options header

      Prevents clickjacking attacks

      What to do: Add "X-Frame-Options: DENY" or "X-Frame-Options: SAMEORIGIN"

    • High

      Missing Content-Security-Policy header

      Controls resources the browser is allowed to load

      What to do: Implement a Content-Security-Policy appropriate for your application

      • ASVS V3.4.3
      • OWASP Secure Headers: OWASP Secure Headers Project recommends Content-Security-Policy: default-src 'self'; form-action 'self'; base-uri 'self'; object-src 'none';…

  2. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1
    • High

      SSL Certificate Expires Soon

      SSL certificate expires in 28 days

      What to do: Renew SSL certificate before expiration

      • NIS2 21(2)(h)
      • IR 2024/2690 9.2(c): Implementing Regulation (EU) 2024/2690, Annex point 9.2(c): Cryptography
      • NIST SC-17: NIST SP 800-53 Rev. 5 SC-17: Public Key Infrastructure Certificates

Need hands-on remediation? Email guard@offseq.com

Keep watching pallapharma.com

This scan found 24 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. The full timeline opens with your unlock code.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
62
Security headers
15
Email security
60
DNS health
80
Network security
20
GDPR outside view
95
Average
55

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

The company operates in the healthcare sector, focusing on pharmaceutical manufacturing and supply. Its business model revolves around producing APIs and FDFs, serving a global market. The domain registration aligns with the company's claimed business, showing transparency and legitimacy. The website's content and design suggest a small-sized enterprise with consistent branding. The use of multilingual plugins indicates an intent to reach international clients. The absence of detailed contact information and certifications limits the visibility of trust signals. Marketing and analytics tools are used moderately, supporting business intelligence efforts. No partner or subsidiary domains were identified, indicating a standalone operation or limited public partnerships.

Security posture

The website employs HTTPS with a valid SSL certificate, ensuring encrypted communications. However, no security headers such as Content-Security-Policy, X-Frame-Options, or X-Content-Type-Options were detected, which are recommended to mitigate common web vulnerabilities. The cookie consent mechanism is present, supporting GDPR compliance, but no privacy policy or terms of service pages were found, representing compliance gaps. No vulnerability disclosures or incident response contacts are provided, which could hinder timely reporting and resolution of security issues. The use of popular plugins and themes necessitates regular updates to avoid vulnerabilities. Overall, the security posture is moderate but requires enhancements in policy transparency and technical safeguards.

Recommendations

  1. Implement and publish a comprehensive privacy policy and terms of service to improve compliance and user trust.
  2. Add security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to enhance protection against common attacks.
  3. Provide clear contact information including emails and phone numbers for general inquiries and security incidents.
  4. Establish a vulnerability disclosure policy or security.txt file to facilitate responsible reporting of security issues.
  5. Regularly audit and update all plugins and themes to mitigate risks from known vulnerabilities.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Palla Pharma Norway
Description
A pharmaceutical company producing active pharmaceutical ingredients (API) and finished dose formulations (FDF) targeting a global market.
Key services
Production of active pharmaceutical ingredients (API), Production of finished dose formulations (FDF)
Content quality
good
Branding
consistent

Technology

Stack
WordPress, jQuery, Google Tag Manager, Google Analytics, Divi Theme, TranslatePress, WPForms, Moove GDPR Cookie Compliance
Frameworks
Divi
Platforms
WordPress
Performance
moderate
Mobile
good
Accessibility
basic
SEO
good

Security

Observed score
75/100
Good practices seen
  • HTTPS enabled
  • Cookie consent mechanism present

Analytics and tracking

Services
Google Analytics, Google Tag Manager
Tracking level
moderate
Privacy practices
basic

Advertising

Ad networks
Google Ads
Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
good
Trustworthiness
moderate

Key observations

  1. Website uses WordPress with Divi theme and several plugins including GDPR compliance and multilingual support.
  2. HTTPS is enabled with good SSL configuration.
  3. Cookie consent mechanism is implemented.
  4. No explicit privacy policy or terms of service pages found in the provided content.
  5. No explicit contact information (email, phone, address) found in the provided HTML snippet.
  6. No security policy or incident response information found.
  7. No vulnerability disclosure or security.txt file detected.
  8. Website content is professional and relevant to pharmaceutical industry.
  9. Google Analytics and Google Tag Manager are used for tracking.
  10. No suspicious or malicious content detected.
Technical notes

Notes

The website is built on WordPress with the Divi theme, leveraging jQuery and several plugins for multilingual support, forms, and GDPR compliance. Hosting is provided by Datacenter.no, as indicated by the nameservers. Performance is moderate with standard optimization practices. The site is mobile-optimized and uses Google Fonts and Google Analytics for enhanced user experience and data collection. The absence of DNSSEC and security headers suggests some technical debt in security hardening. The site uses asynchronous loading for analytics scripts, improving load times. Overall, the technical infrastructure is modern but could benefit from additional security and performance optimizations.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Reviews of this site

Share your experience with pallapharma.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review pallapharma.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.